Regulators in the EU have issued draft recommendations explaining how drug companies and other stakeholders can identify suitable real-world data sources for studies, and what metadata elements they should consider for this purpose.
EU Drafts Recommendations On Identifying Suitable RWD Sources For Studies
EU regulators have developed a draft good practice guide explaining how stakeholders can make use of the Metadata Catalog of RWD Sources, which is expected to be released in late 2023, to identify appropriate sources for specific research questions.
More from Europe
More from Geography
• By
Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.